The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target ...

CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria. However, the disease remains uncontrolled despite antihistamine treatment ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

Nvidia helped pull U.S. stock indexes higher on Tuesday after they stumbled in the morning amid worries about escalations in ...

While there isn’t a definitive cure for cold sores, a multitude of treatments exist which can alleviate symptoms and expedite healing. When it comes to finding the best cold sore treatment ...